tag:blogger.com,1999:blog-36634196.post6459501453390856440..comments2023-10-09T11:33:37.853-05:00Comments on The IN VIVO Blog: Wacky World of Generics: Treximet EditionChris Morrisonhttp://www.blogger.com/profile/04075266444951558159noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-36634196.post-4276371118749985542008-10-28T12:05:00.000-05:002008-10-28T12:05:00.000-05:00So your point about "formulation" or "drug deliver...So your point about "formulation" or "drug delivery" patents being of low value is inaccurate. See, for example, OxyContin, where Purdue's patents were thoroughly litigated and eventually upheld. Another example: Duragesic, where Alza held off the challenge from Mylan.<BR/><BR/>The real issue is the underlying breadth of the claims, and their novelty and non-obviousness. Formulation and drug-delivery patent claims can be as effective at providing appropriate protection for innovative inventions as are compound patents. Once just needs to be sophisticated about understanding the scope of the issued claims and their underlying validity.Anonymousnoreply@blogger.com